Shares of Harmony Biosciences Holdings, Inc. (HRMY) are up 4% on Thursday after the company's Pitolisant Tablets was granted FDA Orphan Drug designation for the treatment of idiopathic hypersomnia (IH), a rare and chronic neurological disease that is characterized by excessive daytime sleepiness.